Hengrui Pharmaceutical announced that its subsidiary Suzhou Shengdia Biomedical Co., Ltd. has received the “Notice of Acceptance” issued by the State Drug Administration, and the marketing license application for injectable Ruikang luzetutamab has been accepted. The drug is intended for the treatment of adult patients with specific lung cancer, based on the results of the phase III clinical trial. There are no HER3-targeting ADCs approved to treat NSCLC in the world. Up to now, the total R&D investment for related projects is about 319.5 million yuan. There is uncertainty about drug development and marketing, and the company will advance the project and disclose progress.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.